Compugen (NASDAQ:CGEN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, January 9th.
According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “
Separately, ValuEngine cut Compugen from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st.
Shares of Compugen (NASDAQ:CGEN) remained flat at $$2.70 during mid-day trading on Tuesday. 193,110 shares of the stock were exchanged, compared to its average volume of 225,359. Compugen has a 1 year low of $2.25 and a 1 year high of $5.40. The stock has a market cap of $138.06, a price-to-earnings ratio of -3.80 and a beta of 0.68.
Compugen (NASDAQ:CGEN) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). equities research analysts expect that Compugen will post -0.73 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of CGEN. Ark Investment Management LLC grew its holdings in Compugen by 104.1% in the 2nd quarter. Ark Investment Management LLC now owns 560,103 shares of the biotechnology company’s stock valued at $2,128,000 after buying an additional 285,653 shares during the period. Susquehanna International Group LLP purchased a new stake in shares of Compugen during the 2nd quarter worth about $162,000. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Compugen by 35.4% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 85,300 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 22,305 shares during the period. Taylor Frigon Capital Management LLC purchased a new stake in shares of Compugen during the 4th quarter worth about $707,000. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Compugen during the 4th quarter worth about $2,381,000. Institutional investors own 17.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/04/compugen-cgen-rating-increased-to-hold-at-zacks-investment-research.html.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Get a free copy of the Zacks research report on Compugen (CGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.